カンジダ症治療の世界市場

カンジダ症治療の世界市場は2030年までに44億米ドルに達する見込み

2024年に32億米ドルと推定されるカンジダ症治療の世界市場は、2024年から2030年にかけてCAGR 5.2%で成長し、2030年には44億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである注射ルートは、CAGR 4.9%を記録し、分析期間終了時には28億米ドルに達すると予測されます。軟膏ルートセグメントは、分析期間中CAGR 6.0％で成長すると推定されます。

米国市場は8億7,760万米ドルと推定、中国はCAGR 8.1％で成長予測

米国のカンジダ症治療市場は、2024年に8億7,760万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.1%として、2030年までに8億6,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界のカンジダ症治療市場- 主要動向と促進要因まとめ

なぜカンジダ症が感染症治療薬の重要な焦点として浮上してきたのか？

カンジダ属、特にカンジダアルビカンスの過剰増殖によって引き起こされるカンジダ症は、その罹患率と潜在的な重症度の増加により、世界の感染症管理における重大な関心事として浮上しています。口腔鵞口瘡や膣イースト菌感染症のような表在性のものは一般的であり、通常は良性であるが、侵襲性カンジダ症は、特にがん患者、移植患者、ICU患者、長期にわたる広域抗生物質投与患者などの免疫不全患者において、生命を脅かす可能性があります。糖尿病のような慢性疾患の増加や、カテーテルや人工呼吸器のような医療機器の広範な使用とともに、このような脆弱な集団の増加が、世界のカンジダ症患者の急増に寄与しています。さらに問題を複雑にしているのは、アゾール系抗真菌薬やエキノカンディン系抗真菌薬など従来の抗真菌薬に対するカンジダ菌の耐性化が進んでいることです。この抗菌薬耐性により、ヘルスケア機関や製薬会社は、現在の治療戦略を早急に再評価し、新たな創薬パイプラインに投資する必要に迫られています。さらに、病院での集団発生に関連した多剤耐性株であるカンジダオーリスの出現により、世界の監視活動が強化され、より効果的で的を絞った治療薬への需要が加速しています。カンジダ症はもはや単なる日和見感染症とはみなされず、ヘルスケアシステムにおける感染制御プロトコル、抗真菌スチュワードシップ、診断能力の堅牢性を測るリトマス試験紙となっています。認知度が高まり、診断技術が向上するにつれ、より多くの症例が特定され、適切に分類されるようになり、以前は十分に認識されていなかった疾患負担が明らかになり、強固で微妙な治療対応が必要となっています。

医薬品イノベーションはどのようにカンジダ症治療パラダイムを再構築しているのか？

治療法の選択肢を拡大し、薬剤耐性の課題に対処することで、医薬品の技術革新はカンジダ症の状況を一変させる上で極めて重要な役割を果たしています。ポリエン系抗真菌薬、アゾール系抗真菌薬、エキノカンディン系抗真菌薬などの伝統的な抗真菌薬は依然として最前線の治療薬であるが、それぞれのクラスにはスペクトル、毒性、薬物動態、耐性の可能性などの点で限界があります。これに対し、複数の製薬企業や研究機関が、新規の作用機序、幅広い活性スペクトル、安全性プロファイルを有する次世代抗真菌薬の開発に取り組んでいます。注目すべき開発のひとつに、テトラゾール系抗真菌薬やグルカン合成酵素阻害薬の登場があり、これらの抗真菌薬はより強力で耐性リスクを低減しています。さらに、イブレキサファンガープ（ファーストインクラスのトリテルペノイド系抗真菌薬）やレザファンギン（長時間作用型エキノカンジン）などの治験薬が後期臨床試験を進行中であり、表在性・浸潤性両方のカンジダ症の治療に有望視されています。リポソーム製剤や標的デリバリーシステムも、全身毒性を最小限に抑えながら薬効を向上させるために研究されています。さらに、モノクローナル抗体や免疫調整剤を含む免疫療法戦略も、難治性感染症の補助療法として研究されています。PCRアッセイ、MALDI-TOF質量分析、次世代シーケンシングのような先進的な診断ツールは、カンジダ属の早期かつ正確な同定をサポートし、より効果的で個別化された治療レジメンを導くために、臨床に組み込まれつつあります。これらの技術革新は、単に治療手段を広げるだけでなく、真菌感染症における精密医療へのシフトを促しています。これは、一刻を争う標的を絞った介入が、回復と重篤な全身合併症や死亡の分かれ目となる病院環境において特に重要です。

カンジダ症治療の需要を牽引するヘルスケア動向と患者層とは？

カンジダ症治療の需要の高まりは、いくつかの交差するヘルスケア動向や患者層の変化に深く影響されています。最も顕著な要因のひとつは、がん治療、臓器移植、自己免疫疾患、HIV/AIDSなどによる免疫不全患者の世界の増加です。侵襲的な医療処置の普及や、中心静脈ライン、人工器官、カテーテルなどの留置器具の使用は、カンジダが血流に入る経路を作り、侵襲性カンジダ症のリスクを著しく高める。集中治療室（ICU）では、カンジダ症は、特に機械的人工呼吸や非経口栄養を必要とする患者において、最も頻繁に報告される真菌感染症の1つとなっています。さらに、膣カンジダ症や粘膜皮膚感染症を再発させる危険因子として知られる糖尿病の世界の増加も、治療ニーズの高まりに寄与しています。現在進行中のCOVID-19パンデミックは、多くの重症患者がステロイドの使用や長期入院により二次的な真菌感染症を発症したため、この負担をさらに悪化させています。公衆衛生の面では、真菌感染症に対する認識が高まり、診断へのアクセスが改善されたことで、高所得層と低資源層の両方で、より多くの症例が発見されています。また、併存疾患を抱えやすく免疫力が低下しやすい高齢化社会も、治療対象として増加しています。同時に、医療システムはより厳格な抗真菌薬管理プロトコルを採用しており、有効でありながら耐性菌が発生しにくい新しい治療薬が求められています。このような人口動態と臨床の変化を総合すると、様々な患者集団やヘルスケア環境に対応できる、安全で有効かつ汎用性の高いカンジダ症治療の必要性が高まっています。

カンジダ症治療市場の将来を形作る戦略的・規制的動向とは？

カンジダ症治療市場の成長は、進化する臨床ニーズ、市場力学、世界ヘルスの優先順位を反映するいくつかの戦略的および規制的動向によって牽引されています。主要な促進要因は、希少疾病用医薬品（Orphan Drug）、ファストトラック（Fast Track）指定、FDAが付与する適格感染症製品（QIDP）ラベルなどの規制上の優遇措置により、大手製薬企業やバイオテクノロジー新興企業の抗真菌薬開発への投資が増加していることです。これらのプログラムは、希少だが深刻な真菌感染症に対する新しい治療法の開発を加速させることを目的としており、市場独占権の延長や承認経路の合理化を提供しています。複雑な研究課題に対処し、開発のボトルネックを克服するためにリソースをプールする、学界、産業界、公衆衛生機関の戦略的共同研究も増加しています。CDCやWHOのような組織が抗菌薬耐性菌のモニタリングや真菌病原体の追跡を優先しているように、抗真菌薬サーベイランスが世界の保健政策に組み込まれていることも大きな動向です。その結果、治療介入を補完する診断支援、治療ガイドライン、感染対策への資金提供や関心が高まっています。市場力学はまた、旧来の抗真菌薬のジェネリック医薬品の利用可能性の拡大にも影響されており、特に発展途上国では、手頃な価格で入手できるようになりました。同時に、新薬の革新的な価格設定とアクセスモデルが試され、収益性と世界の健康の公平性のバランスが取られています。技術面では、デジタルヘルスプラットフォーム、電子カルテ、臨床意思決定支援ツールの融合により、治療効果や耐性菌の動向をリアルタイムでモニタリングすることが可能になっています。これらの戦略的および規制状況は、現在の市場情勢を形成しているだけでなく、治療イノベーションを通じてカンジダ症を管理するための、より迅速でデータ主導の、世界に協調したアプローチへの道を開いています。

セグメント

投与経路（注射、軟膏、経口）、薬剤タイプ（ポリエン系、アゾール系、エキノカンジン系、その他薬剤タイプ）、解剖学的タイプ（口腔カンジダ症、外陰カンジダ症、皮膚カンジダ症、侵襲性カンジダ症、全身性カンジダ症）、エンドユーザー（病院・診療所、小売薬局、その他エンドユーザー）

調査対象企業の例（注目の36社）

• Ablynx NV
• Amgen Inc.
• Astellas Pharma Inc.
• Basilea Pharmaceutica Ltd
• Bayer AG
• Cidara Therapeutics Inc.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• Ferrer Internacional S.A.
• Gilead Sciences Inc.
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Mycovia Pharmaceuticals Inc.
• Novartis AG
• NovaBiotics Ltd.
• Pfizer Inc.
• SCYNEXIS Inc.
• Teva Pharmaceutical Industries Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Candidiasis Therapeutics Market to Reach US$4.4 Billion by 2030

The global market for Candidiasis Therapeutics estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Injection Route, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Ointment Route segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$877.6 Million While China is Forecast to Grow at 8.1% CAGR

The Candidiasis Therapeutics market in the U.S. is estimated at US$877.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$864.6 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Candidiasis Therapeutics Market - Key Trends & Drivers Summarized

Why Has Candidiasis Emerged as a Critical Focus in Infectious Disease Therapeutics?

Candidiasis, caused by the overgrowth of Candida species-particularly Candida albicans-has emerged as a critical concern in global infectious disease management due to its increasing incidence and potential severity. While superficial forms such as oral thrush and vaginal yeast infections are common and typically benign, invasive candidiasis can be life-threatening, particularly among immunocompromised individuals, including cancer patients, transplant recipients, ICU patients, and those on long-term broad-spectrum antibiotics. The rise in such vulnerable populations, alongside an uptick in chronic diseases like diabetes and the widespread use of medical devices such as catheters and ventilators, has contributed to a surge in candidiasis cases globally. Complicating the matter further is the growing resistance of Candida species to conventional antifungal agents, including azoles and echinocandins. This antimicrobial resistance has prompted healthcare institutions and pharmaceutical firms to urgently reevaluate current treatment strategies and invest in new drug discovery pipelines. Furthermore, the emergence of Candida auris, a multidrug-resistant strain linked to hospital outbreaks, has heightened global surveillance efforts and accelerated the demand for more effective and targeted therapeutics. Candidiasis is no longer viewed merely as an opportunistic infection-it has become a litmus test for the robustness of infection control protocols, antifungal stewardship, and diagnostic capabilities within healthcare systems. As awareness increases and diagnostic techniques improve, more cases are being identified and appropriately categorized, revealing a previously under-recognized disease burden that necessitates a robust and nuanced therapeutic response.

How Are Pharmaceutical Innovations Reshaping Candidiasis Treatment Paradigms?

Pharmaceutical innovation is playing a pivotal role in transforming the landscape of candidiasis therapeutics by expanding treatment options and addressing drug resistance challenges. Traditional antifungals such as polyenes, azoles, and echinocandins remain the frontline treatments, but each class has limitations in terms of spectrum, toxicity, pharmacokinetics, or resistance potential. In response, several pharmaceutical companies and research institutions are developing next-generation antifungal agents with novel mechanisms of action, broader activity spectra, and improved safety profiles. One notable development is the emergence of tetrazoles and glucan synthase inhibitors, which offer enhanced potency and reduced resistance risks. Additionally, investigational agents like ibrexafungerp (a first-in-class triterpenoid antifungal) and rezafungin (a long-acting echinocandin) are progressing through late-stage clinical trials, showing promise for treating both superficial and invasive forms of candidiasis. Liposomal formulations and targeted delivery systems are also being explored to improve drug efficacy while minimizing systemic toxicity. Furthermore, immunotherapeutic strategies, including monoclonal antibodies and immune modulators, are under investigation as adjunctive therapies for recalcitrant infections. Advanced diagnostic tools like PCR assays, MALDI-TOF mass spectrometry, and next-generation sequencing are being integrated into clinical practice to support early and precise identification of Candida species, guiding more effective and personalized treatment regimens. These innovations are not just broadening the therapeutic arsenal-they are also catalyzing a shift toward precision medicine in fungal infections. This is particularly crucial in hospital settings where time-sensitive, targeted interventions can mean the difference between recovery and severe systemic complications or mortality.

What Healthcare Trends and Patient Demographics Are Driving the Demand for Candidiasis Therapeutics?

The rising demand for candidiasis therapeutics is deeply influenced by several intersecting healthcare trends and shifting patient demographics. One of the most prominent factors is the global increase in immunocompromised populations due to cancer therapies, organ transplantation, autoimmune diseases, and HIV/AIDS-all of which heighten susceptibility to fungal infections. The proliferation of invasive medical procedures and the use of indwelling devices like central lines, prosthetics, and catheters create pathways for Candida to enter the bloodstream, significantly raising the risk of invasive candidiasis. In intensive care units (ICUs), candidiasis has become one of the most frequently reported fungal infections, particularly among patients requiring mechanical ventilation or parenteral nutrition. Additionally, the global rise in diabetes-a known risk factor for recurrent vaginal candidiasis and mucocutaneous infections-is contributing to elevated therapeutic needs. The ongoing COVID-19 pandemic has further exacerbated this burden, as many critically ill patients developed secondary fungal infections due to steroid use and prolonged hospitalization. On the public health front, increasing awareness about fungal infections and improved access to diagnostics are uncovering more cases in both high-income and low-resource settings. Aging populations, which are more prone to comorbidities and weakened immune systems, also represent a growing treatment cohort. Simultaneously, health systems are adopting stricter antifungal stewardship protocols, requiring new therapeutics that are effective yet resist the development of resistance. Collectively, these demographic and clinical shifts are reinforcing the need for safe, effective, and versatile candidiasis treatment options that can be deployed across a spectrum of patient populations and healthcare environments.

What Strategic and Regulatory Trends Are Shaping the Future of the Candidiasis Therapeutics Market?

The growth in the candidiasis therapeutics market is driven by several strategic and regulatory trends that reflect evolving clinical needs, market dynamics, and global health priorities. A major driver is the increasing investment in antifungal drug development by both large pharmaceutical firms and biotechnology startups, spurred by regulatory incentives such as Orphan Drug status, Fast Track designation, and the Qualified Infectious Disease Product (QIDP) label granted by the FDA. These programs aim to accelerate the development of new treatments for rare but serious fungal infections, providing extended market exclusivity and streamlined approval pathways. Strategic collaborations between academia, industry, and public health organizations are also on the rise, pooling resources to address complex research challenges and overcome development bottlenecks. Another significant trend is the integration of antifungal surveillance into global health agendas, with organizations like the CDC and WHO prioritizing antimicrobial resistance monitoring and fungal pathogen tracking. This has resulted in greater funding and attention toward diagnostic support, treatment guidelines, and infection control measures that complement therapeutic interventions. Market dynamics are also influenced by the expanding availability of generics for older antifungals, which increases affordability and access, particularly in developing nations. At the same time, innovative pricing and access models are being tested for newer agents to balance profitability with global health equity. On the technological front, the convergence of digital health platforms, electronic medical records, and clinical decision support tools is enabling real-time monitoring of treatment efficacy and resistance trends. These strategic and regulatory forces are not only shaping the current market landscape but are also paving the way for a more responsive, data-driven, and globally coordinated approach to managing candidiasis through therapeutic innovation.

SCOPE OF STUDY:

The report analyzes the Candidiasis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Injection Route, Ointment Route, Oral Route); Drug Type (Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type, Other Drug Types); Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis); End-Use (Hospitals & Clinics End-Use, Retail Pharmacies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Ablynx NV
• Amgen Inc.
• Astellas Pharma Inc.
• Basilea Pharmaceutica Ltd
• Bayer AG
• Cidara Therapeutics Inc.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• Ferrer Internacional S.A.
• Gilead Sciences Inc.
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Mycovia Pharmaceuticals Inc.
• Novartis AG
• NovaBiotics Ltd.
• Pfizer Inc.
• SCYNEXIS Inc.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Candidiasis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Fungal Infections Throws the Spotlight on Candidiasis as a Growing Public Health Concern
  • Increased Immunocompromised Populations Accelerate Demand for Effective Antifungal Therapies
  • Expansion of Invasive Candidiasis Cases in ICU Settings Strengthens the Business Case for Rapid-Acting Treatments
  • Growing Antifungal Resistance Expands the Addressable Market Opportunity for Novel Drug Classes
  • Development of Broad-Spectrum and Targeted Antifungals Spurs Innovation in Candidiasis Therapeutic Pipelines
  • Rising Use of Immunosuppressive Therapies in Cancer and Transplant Patients Drives Long-Term Treatment Demand
  • Advancements in Diagnostic Tools Open New Vistas for Timely and Precise Candidiasis Treatment Strategies
  • Hospital-Acquired Infections and Sepsis Linkages Generate Demand for Aggressive Fungal Infection Control Measures
  • Pediatric and Geriatric Vulnerability Sustains Focus on Safer, Lower-Toxicity Candidiasis Drug Formulations
  • Growing Interest in Probiotics and Microbiome Therapies Enhances R&D in Preventive and Adjunctive Treatments
  • Combination Therapy Strategies Gain Traction to Combat Resistance and Broaden Treatment Efficacy
  • Oral and Topical Form Innovations Drive Adoption in Mild-to-Moderate Candidiasis Treatment Segments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Candidiasis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Candidiasis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Candidiasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Injection Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Injection Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Injection Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Ointment Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Ointment Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Ointment Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cutaneous Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cutaneous Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Cutaneous Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Invasive Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Invasive Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Invasive Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Systemic Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Systemic Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Systemic Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oral Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oral Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Oral Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Vulvovaginal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Vulvovaginal Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Vulvovaginal Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Polyene Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Polyene Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Polyene Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Azole Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Azole Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Azole Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Echinocandin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Echinocandin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Echinocandin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• JAPAN
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• CHINA
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• EUROPE
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Candidiasis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Candidiasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• FRANCE
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• GERMANY
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Candidiasis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• INDIA
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Candidiasis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Candidiasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Candidiasis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Candidiasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030
• AFRICA
  • Candidiasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Candidiasis Therapeutics by Administration Route - Injection Route, Ointment Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Candidiasis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Injection Route, Ointment Route and Oral Route for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Candidiasis Therapeutics by Anatomy Type - Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Candidiasis Therapeutics by Anatomy Type - Percentage Breakdown of Value Sales for Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis, Oral Candidiasis and Vulvovaginal Candidiasis for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Candidiasis Therapeutics by End-Use - Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Candidiasis Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Retail Pharmacies End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Candidiasis Therapeutics by Drug Type - Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Candidiasis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Polyene Drug Type, Azole Drug Type, Echinocandin Drug Type and Other Drug Types for the Years 2014, 2025 & 2030

IV. COMPETITION